Sarepta rockets up after FDA approves its controversial Duchenne drug
After years of fierce debate in a seesaw battle over the fate of Sarepta’s Duchenne muscular dystrophy drug eteplirsen, the FDA has granted the drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
